임상시험 이미징 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Clinical Trial Imaging Market size is expected to reach USD 3.79 Billion in 2034 from USD 1.80 Billion (2025) growing at a CAGR of 8.61% during 2026-2034.

The Global Clinical Trial Imaging Market is expanding rapidly due to increasing number of clinical trials in oncology, cardiology, and neurology. Imaging plays a vital role in evaluating treatment efficacy and monitoring disease progression. Pharmaceutical and biotechnology companies are increasingly outsourcing imaging services to specialized providers.

Growth drivers include rising R&D investments, growing demand for biomarker-driven trials, and advancements in imaging modalities such as MRI and CT scans. Regulatory emphasis on accurate data collection has strengthened the adoption of standardized imaging protocols. Additionally, the rise of personalized medicine has further fueled demand for advanced imaging solutions.

Future prospects are promising with integration of AI and cloud-based imaging platforms enhancing data analysis and collaboration. Expansion of clinical research activities in emerging markets will further support growth. Continuous technological advancements and increasing drug development pipelines are expected to sustain long-term market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product and Services

• Services
• Software

By Modality

• Computed Tomography
• Magnetic Resonance Imaging
• Echocardiography
• Nuclear Medicine
• Positron Emission Tomography
• X-ray
• Ultrasound
• Optical Coherence Tomography
• Others

By Application

• Oncology
• Neurology
• Endocrinology
• Cardiology
• Dermatology
• Hematology
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Medical Device Manufacturers
• Academic and Government Research Institutes
• Others

COMPANIES PROFILED

• Navitas Life Sciences, Resonance Health Ltd, BioTelemetry a Philips Company, IXICO plc, ICON plc, Image Core Lab, anagram 4 clinical trials, Quotient Sciences, Radiant Sage LLC, Worldcare Clinical, Clario, Parexel International Corporation, Median Technologies, Perspectum, Invicro LLC
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CLINICAL TRIAL IMAGING MARKET: BY PRODUCT AND SERVICES 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product And Services
• 4.2. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CLINICAL TRIAL IMAGING MARKET: BY MODALITY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Modality
• 5.2. Computed Tomography Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Magnetic Resonance Imaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Echocardiography Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Nuclear Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Positron Emission Tomography Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. X-ray Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Ultrasound Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Optical Coherence Tomography Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CLINICAL TRIAL IMAGING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Endocrinology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CLINICAL TRIAL IMAGING MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Pharmaceutical and Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Medical Device Manufacturers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Academic and Government Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CLINICAL TRIAL IMAGING MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product And Services
  • 8.2.2 By Modality
  • 8.2.3 By Application
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product And Services
  • 8.3.2 By Modality
  • 8.3.3 By Application
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product And Services
  • 8.4.2 By Modality
  • 8.4.3 By Application
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product And Services
  • 8.5.2 By Modality
  • 8.5.3 By Application
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product And Services
  • 8.6.2 By Modality
  • 8.6.3 By Application
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CLINICAL TRIAL IMAGING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Navitas Life Sciences
  • 10.2.2 Resonance Health Ltd
  • 10.2.3 BioTelemetry (A Philips Company)
  • 10.2.4 IXICO Plc
  • 10.2.5 ICON Plc
  • 10.2.6 Image Core Lab
  • 10.2.7 Anagram 4 Clinical Trials
  • 10.2.8 Quotient Sciences
  • 10.2.9 Radiant Sage LLC
  • 10.2.10 Worldcare Clinical
  • 10.2.11 Clario
  • 10.2.12 Parexel International Corporation
  • 10.2.13 Median Technologies
  • 10.2.14 Perspectum
  • 10.2.15 Invicro LLC